Skip to main content
New Treatment Option

New Treatment for Long-Standing Persistent Atrial Fibrillation

If your atrial fibrillation has lasted for more than a year, there's new hope for effective treatment. Hybrid AF™ Therapy with the EPi-Sense device is the first and only FDA PMA approved minimally invasive ablation therapy for long-standing persistent atrial fibrillation patients.

Hybrid AF Therapy combines two types of ablation therapy to treat two key trigger areas for AF:

Hybrid Ablation Epicardial

Epicardial ablation treats the outside of the heart, on the back (posterior) of the atrium, another known trigger area for AF.

Hybrid Ablation Endocardial

Endocardial radiofrequency (RF) ablation treats the inside of the heart at the pulmonary veins. This is a key trigger area for atrial fibrillation.

This way doctors can treat two important trigger areas for atrial fibrillation. Learn more about trigger areas for atrial fibrillation.


Moreover, Hybrid AF Therapy results in:
  • 90% fewer atrial fibrillation episodes for most people (79%)1
  • Allows people to feel better, both physically and emotionally, and to have fewer symptoms2


1. DeLurgio, D.B., et al. (2021). Hybrid epicardial-endocardial RF ablation vs. endocardial catheter ablation for long-standing persistent atrial fibrillation treatment: Results from CONVERGE randomized controlled trial. International AF Symposium.

2. IFU for EPi-Sense® Guided Coagulation System Data: PMA# P200002